Providers

The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.

Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.

Presenters explored the real-world evidence in support of biosimilars at the Academy of Managed Care Pharmacy 2024 annual meeting.

While health plans often employ reimbursement rates as a tool to incentivize provider participation within their networks, study results showed reimbursement rates for office visits with medical/surgical clinicians were on average 22% higher than behavioral health clinicians.

Patients with atopic dermatitis (AD) may have an increased risk of headache disorder and migraines.

News from Strategic Alliance Partners of The American Journal of Managed Care.

The therapy bridges activated factors IX and X to mimic the function of missing or deficient factor VIII.

A new survey has found that most patients who have generalized myasthenia gravis who switched from eculizumab to ravulizumab preferred the latter.

In a registry-based analysis, more hospitalized children with SCD and COVID-19 had severe infection requiring supplemental oxygen, compared with the general population.

A single injection of a gene therapy was well tolerated and showed the potential to control exudation in patients with neovascular age-related macular degeneration (wet AMD).

The LIFE-T1D model, demonstrated an ability to estimate the lifetime risk of heart disease among several groups of people with type 1 diabetes (T1D).

Michael Morse, MD, FACP, MHS, professor of medicine at Duke University School of Medicine and medical oncologist at Duke Cancer Center, discusses the etiologies of hepatocellular carcinoma (HCC) and how clinicians can tailor treatment for patients with varied levels of liver function.

A recent study suggests treatment with glucocorticoids after loss of ambulation can preserve late-stage functional abilities, respiratory function, and cardiac function in patients with Duchenne muscular dystrophy (DMD).

Ari Green, MD, University of California, San Francisco, discusses the promising results observed in current remyelination trials in multiple sclerosis (MS) and the patient-specific features that may influence therapy outcomes.

The introduction of momelotinib to treat myelofibrosis with anemia can result in small savings due to reduced transfusion-related costs, according to a budget impact model.

Patients with radiographic axial spondyloarthritis (ax-SpA) and a high risk of radiographic progression had similar low progression on both secukinumab and an adalimumab biosimilar.

Treatment and management of multiple myeloma (MM) is continuously evolving, and in this analysis, investigators discuss ever-present issues and potential solutions to optimize care for this patient population.

Young breast cancer survivors without a specific genetic mutation have a lower risk of developing second primary breast cancer within 10 years of diagnosis.

Authors conducted a systematic literature review to gather evidence on the appropriateness of recommended treatments for locally advanced non–small cell lung cancer (LA-NSCLC) from the American Radium Society Appropriate Use Criteria Thoracic Committee.

The new playbook details voluntary best practices for value-based care (VBC) payment arrangements and is part of an effort to increase VBC adoption in the private sector.

This feature series delves into how biases shed light on deeply ingrained stereotypes and prejudices that exist within the structure of US maternal health care, according to experts.